To monitor adverse events related to Tdap vaccination in the United States.
Analyzed reports from the Vaccine Adverse Event Reporting System (VAERS).
Focused on maternal Tdap vaccination data from July 2015 to September 2023.
Most reported adverse events were classified as non-serious.
Common adverse events correlated with pre- and post-licensure findings.
No new or unexpected adverse events were identified.
Abstract
Most reports were non-serious and the most common AEs were similar to those observed in pre- and post-licensure studies. No new or unexpected AE was identified.